New drug targets rare gene fault in advanced cancers

NCT ID NCT07128303

Recruiting now Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called GS-5319 in adults with advanced solid tumors that lack a specific gene (MTAP). The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 178 people whose cancer has not responded to standard treatments will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
START - Centro Oncológico Clara Campal
RECRUITING

Madrid, 28050, Spain
START Madrid - FJD - Hospital Fundación Jiménez Díaz - Phase I Clinical Trials Unit
RECRUITING

Madrid, 28040, Spain
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Vall d'Hebron Institute of Oncology (VHIO)
RECRUITING

Barcelona, 08035, Spain
Yonsei University Severance Hospital
RECRUITING

Seoul, '06273, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.